Key Takeaways
- Origin Agritech reported FY2025 revenue of RMB 91.3 million, down year-over-year amid factory upgrades and portfolio optimization
- The company expanded its corn seed pipeline with four new varieties and multiple regulatory approvals
- R&D investment increased, supported by new research platforms and gene-editing authorizations
- Management outlined progress in its multi-stage recovery and growth strategy through 2026 and beyond
Origin Agritech FY2025 Financial Performance
Origin Agritech Ltd. (NASDAQ: SEED) reported financial results for the fiscal year ended September 30, 2025, reflecting a transitional year marked by infrastructure upgrades and strategic repositioning. Revenue for the year totaled RMB 91.3 million (US$12.8 million), compared with RMB 113.4 million (US$16.2 million) in fiscal year 2024. The decline was primarily attributed to modernization at the company’s Xinjiang production facility, which reduced external seed processing services, alongside lower sales of non-proprietary varieties.
Total operating expenses increased to RMB 64.2 million (US$9.0 million), driven by higher spending across research and development, general and administrative, and selling activities. Net loss attributable to Origin Agritech was RMB 53.3 million (US$7.5 million), compared with net income of RMB 20.7 million (US$3.0 million) in the prior year.
Product Pipeline and Regulatory Progress at Origin Agritech
During fiscal 2025, Origin Agritech launched four new corn varieties—Jingke 317, Jinqiao 8, Xundan 203, and Aoyu 728—at its Industry Summit. Several of these products advanced through China’s regulatory system, including national trial approvals for Jingke 317 and Aoyu 728, multi-province approval for Jinqiao 8, and provincial approval for Xundan 203.
The company also strengthened its distribution network, hosting a seed industry summit in Zhengzhou that attracted more than 700 distributor partners, reflecting continued engagement across its sales ecosystem.
Research, Production, and Strategic Direction
Origin Agritech expanded its R&D footprint by establishing four provincial and ministerial research platforms and accumulating more than 200,000 corn germplasm resources. The company also received authorization for multiple gene-editing traits related to plant architecture and disease resistance.
On the production side, Origin’s Xinjiang facility resumed full-scale operations in August 2025, operating a fully automated seed processing line designed to improve quality control and throughput.
Mr. Weibin Yan, CEO of Origin Agritech, stated, “Fiscal year 2025 has been a year of recovery for Origin Agritech. We have fully restored our team, research capabilities, seed production and processing facilities, and sales network infrastructure, and we are now ready to march forward under our renewed leadership.”
Liquidity and Outlook
As of September 30, 2025, Origin Agritech reported cash and cash equivalents of RMB 15.9 million (US$2.2 million), supported by increased financing activity during the year. Management reaffirmed its three-stage strategic plan, positioning fiscal 2025 and 2026 as recovery years ahead of planned expansion and commercialization initiatives.
Read the entire financial results.
1 Comment